NR3C2 and type 2 diabetes mellitus: Finerenone, the first novel non-steroidal MRA approved worldwide for type 2 DM (T2D)-associated chronic kidney disease (CKD) [155], exerts its effects by interacting with multiple MR sites in the glomeruli, renal tubules, and myocardium.